Business Overview

GPCRs are important drug targets for a variety of indications. However, due to their special structures, seven-transmembrane with short extracellular domains, the development of antibody drugs against them with high specificities and desired functions has been challenging.


Founded on revolutionary membrane protein technologies, LiberoThera has established drug discovery platform for generating quality antibodies against the challenging targets. LiberoThera is developing novel therapeutic candidates targeting physiologically important membrane proteins, such as GPCRs, in collaboration with multiple partners.